Technical Report Gastroenterology General Surgery Transplantation
Does an enhanced recovery pathway reduce time to diagnosis in adults with type 2 diabetes? A case series

Does an enhanced recovery pathway reduce time to diagnosis in adults with type 2 diabetes? A case series

Authors

Omar Patel

Omar Patel

Hamad Medical Corporation, Cuba

Mei Osei

Mei Osei

Singapore General Hospital, Spain

Corresponding
Yusuf Kim

Yusuf Kim

St Thomas' Hospital, Oman

Yusuf Larsen

Yusuf Larsen

Royal Melbourne Hospital, Bangladesh

Published

August 30, 2026

Paper ID

PAP-000085

Status

Published

DOI

10.65712/tmj.test000343

Does an enhanced recovery pathway reduce time to diagnosis in adults with type 2 diabetes? A case series

Advance Services

Create Content

Video • Presentation • Poster

From $97.00 per format

Abstract

Background: Guidelines make only a weak recommendation on an enhanced recovery pathway. Methods: Eligible participants were adults with type 2 diabetes. Results: 2269 participants were included (median age 59 years). 613 participants were included (median age 62 years). Conclusion: Future work should test an enhanced recovery pathway in a pragmatic multicentre trial.

Introduction

The cost of time to diagnosis to health systems is substantial. Guidelines make only a weak recommendation on an enhanced recovery pathway. time to diagnosis remains a leading cause of avoidable harm among adults with type 2 diabetes.

Earlier studies of an enhanced recovery pathway were small or single-centre. time to diagnosis remains a leading cause of avoidable harm among adults with type 2 diabetes.

time to diagnosis remains a leading cause of avoidable harm among adults with type 2 diabetes. Guidelines make only a weak recommendation on an enhanced recovery pathway. The cost of time to diagnosis to health systems is substantial.

Discussion

Implementation will depend on staffing, cost and local protocols. Strengths include the sample size and blinded outcome assessment.

Implementation will depend on staffing, cost and local protocols. Residual confounding cannot be excluded.

Future work should test an enhanced recovery pathway in a pragmatic multicentre trial. Strengths include the sample size and blinded outcome assessment. Residual confounding cannot be excluded.

Strengths include the sample size and blinded outcome assessment. Implementation will depend on staffing, cost and local protocols. Residual confounding cannot be excluded.

Conclusions

An enhanced recovery pathway merits wider use for adults with type 2 diabetes to improve time to diagnosis.

References

1. Larsen E, Lindqvist Z, et al. Early enteral nutrition and surgical site infection. JAMA. 2014;295(10):202-1101.

2. Lindqvist D, Haddad X, et al. Pharmacist-led medication review and chronic pain scores. BMJ. 2021;327(4):592-958.

3. Zhang O, Ibrahim M, et al. Telemedicine follow-up and 30-day readmission. JAMA. 2018;255(1):224-1660.

4. Farouk R, Osei F, et al. SGLT2 inhibitors and patient satisfaction. Lancet. 2008;322(12):782-998.

5. Ahmed N, Costa Z, et al. Early enteral nutrition and health-related quality of life. Lancet. 2012;375(12):548-1402.

6. Farouk U, Dubois Y, et al. Early mobilisation and acute kidney injury. JAMA. 2009;160(2):238-1211.

7. Farouk Y, Kaur L, et al. Telemedicine follow-up and ventilator-free days. Crit Care Med. 2012;143(12):469-1562.

8. Zhang B, Kowalski M, et al. Tranexamic acid and health-related quality of life. Pediatrics. 2017;348(6):143-1723.

Appendices

Supplementary tables are available on request.

Materials and Methods

We conducted a case series across 8 centres between 2018 and 2024. Missing data were handled with multiple imputation. Analyses were adjusted for age, sex and baseline severity. The primary outcome was time to diagnosis, assessed blind to allocation.

Eligible participants were adults with type 2 diabetes. The primary outcome was time to diagnosis, assessed blind to allocation. Analyses were adjusted for age, sex and baseline severity.

Analyses were adjusted for age, sex and baseline severity. Eligible participants were adults with type 2 diabetes. The primary outcome was time to diagnosis, assessed blind to allocation. We conducted a case series across 4 centres between 2018 and 2022.

Results

Effects were consistent across prespecified subgroups. time to diagnosis occurred in 15% of the intervention group versus 32% of controls. time to diagnosis occurred in 7% of the intervention group versus 36% of controls.

time to diagnosis occurred in 15% of the intervention group versus 20% of controls. 4635 participants were included (median age 33 years). Serious adverse events were rare and similar between groups.

1356 participants were included (median age 62 years). The adjusted odds ratio was 0.63 (95% CI 0.31 to 0.67). The adjusted odds ratio was 0.68 (95% CI 0.31 to 0.93). 1050 participants were included (median age 40 years).

GroupnEvents
Male18942
Male3119
Control67624
Centre B33382
Age < 6533093
TABLE 1: Adverse events
Values are n (%) unless stated otherwise.
Figure 1
FIGURE 1: Trend in time to diagnosis
Shown for adults with type 2 diabetes; error bars are 95% confidence intervals.
Figure 2
FIGURE 2: Distribution of time to diagnosis
Shown for adults with type 2 diabetes; error bars are 95% confidence intervals.

time to diagnosis occurred in 19% of the intervention group versus 16% of controls. time to diagnosis occurred in 22% of the intervention group versus 17% of controls. Effects were consistent across prespecified subgroups. Serious adverse events were rare and similar between groups.